Wave Life Sciences revenue WVE
Sales by quarter and over the last twelve months, from 2015.
- Last 12 months, to Sep 30, 2026
- $70.9M
- Latest quarter, Q3 FY26
- $13.2M
- +73% on a year earlier
- Fiscal year 2025
- $42.7M
- −62% on the year before
Wave Life Sciences' revenue was $70.9M over the twelve months to Sep 30, 2026.
In its latest quarter, Q3 FY26, it was $13.2M, up 73% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 22% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $42.7M | −62% |
| FY2023 | $113.3M | +3005% |
| FY2022 | $3.6M | n/a |
| FY2021 | n/a | n/a |
| FY2020 | $20.1M | +26% |
| FY2019 | $16M | +11% |
| FY2018 | $14.4M | +270% |
| FY2017 | $3.9M | n/a |
| FY2016 | n/a | n/a |
| FY2015 | $152K | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $13.2M | +73% | $70.9M | |
| Q2 FY26 | $2.3M | −74% | $65.4M | |
| Q1 FY26 | $38.2M | +317% | $71.8M | |
| Q4 FY25 | $17.2M | n/a | $42.7M | |
| Q3 FY25 | $7.6M | n/a | n/a | |
| Q2 FY25 | $8.7M | −56% | n/a | |
| Q1 FY25 | $9.2M | −27% | n/a | |
| Q2 FY24 | $19.7M | −11% | $110.5M | |
| Q1 FY24 | $12.5M | −3% | $112.9M | |
| Q4 FY23 | $29.1M | +2245% | $113.3M | |
| Q3 FY23 | $49.2M | +17168% | $85.5M | |
| Q2 FY23 | $22.1M | +5795% | $36.6M |
Against its peers
Companies in Drug Manufacturers - General nearest Wave Life Sciences' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| WVEWave Life Sciences | $70.9M | |
| COLLCollegium Pharmaceutical | $808.2M | +14% a year |
| ABUSArbutus Biopharma | $181.7M | |
| ZVRAZevra Therapeutics | $136.1M | +119% a year |
| IRWDIronwood Pharmaceuticals | $389.3M | +26% a year |
| PBYIPuma Biotechnology | $231.2M | −3% a year |
| ARVNArvinas | $316.7M | −15% a year |
| CRMDCorMedix | $462.2M | +281% a year |
| AMPHAmphastar Pharmaceuticals | $730M | +1% a year |
| OMEROmeros | n/m | |
| ANABAnaptysbio | n/m | |
| Peer median | $353M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Wave Life Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.